Key result
Aortic valve papillary fibroelastoma remains stable over ~5 years and resolves with surgical resection.
Why the study?
Papillary fibroelastoma combined with rheumatic heart disease is extremely rare, and the tumor growth rate is unknown.
Case Report (n=1)
No
Papillary fibroelastomas may be slow-growing, but surgical resection is the preferred treatment to prevent serious complications.
May support conservative surveillance in select stable cases; leaves open need for larger series to guide aortic fibroelastoma management in rheumatic heart disease.
BACKGROUND: Papillary fibroelastoma (PFE) is a rare primary cardiac neoplasm that is usually discovered incidentally at autopsy or during cardiac surgery. PFE combined with rheumatic heart disease (RHD) is extremely rare, and only a few cases have been reported. Additionally, the growth rate of the tumor is unknown. CASE PRESENTATION: Here, we present a very rare case of PFE of the aortic valve combined with RHD, which were identified in a female patient who survived for 5 years without surgical intervention, and who subsequently underwent successful surgical treatment. CONCLUSIONS: PFEs may be generally slow-growing tumors, however, the better treatment of choice may be surgery because it produces good curative effects with very low risk of complications, while preventing serious disease consequences.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2016) conducted a case report in Papillary fibroelastoma of the aortic valve and rheumatic heart disease (n=1). Surgical resection and valve replacement was evaluated on Tumor growth and surgical outcome. A papillary fibroelastoma of the aortic valve in a patient with rheumatic heart disease did not grow significantly over 5 years and was successfully treated with surgical resection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: